These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 35212456)

  • 1. Population pharmacokinetic modeling and simulations of berotralstat for prophylactic treatment of attacks of hereditary angioedema.
    Mathis A; Sale M; Cornpropst M; Sheridan WP; Ma SC
    Clin Transl Sci; 2022 Apr; 15(4):1027-1035. PubMed ID: 35212456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacological and clinical study results of Berotralstat Hydrochloride for long-term prophylactic treatment of hereditary angioedema].
    Orui S; Nozue H; Kobayashi S; Fujioka M; Maekawa Y
    Nihon Yakurigaku Zasshi; 2021; 156(6):382-390. PubMed ID: 34719573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Berotralstat: First Approval.
    Lee A
    Drugs; 2021 Feb; 81(3):405-409. PubMed ID: 33646555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Berotralstat (BCX7353) is a novel oral prophylactic treatment for hereditary angioedema: Review of phase II and III studies.
    Manning ME; Kashkin JM
    Allergy Asthma Proc; 2021 Jul; 42(4):274-282. PubMed ID: 34127176
    [No Abstract]   [Full Text] [Related]  

  • 5. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial.
    Zuraw B; Lumry WR; Johnston DT; Aygören-Pürsün E; Banerji A; Bernstein JA; Christiansen SC; Jacobs JS; Sitz KV; Gower RG; Gagnon R; Wedner HJ; Kinaciyan T; Hakl R; Hanzlíková J; Anderson JT; McNeil DL; Fritz SB; Yang WH; Tachdjian R; Busse PJ; Craig TJ; Li HH; Farkas H; Best JM; Clemons D; Cornpropst M; Dobo SM; Iocca HA; Kargl D; Nagy E; Murray SC; Collis P; Sheridan WP; Maurer M; Riedl MA
    J Allergy Clin Immunol; 2021 Jul; 148(1):164-172.e9. PubMed ID: 33098856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and optimization of orally bioavailable and potent plasma Kallikrein inhibitors bearing a quaternary carbon.
    Zhang W; Vadlakonda S; Wu M; Chintareddy V; Vogeti LN; Juarez L; Muppa S; Parker C; Kellogg-Yelder D; Williams J; Polach K; Chen X; Raman K; Babu YS; Kotian P
    Bioorg Med Chem; 2022 Nov; 73():117035. PubMed ID: 36208543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Berotralstat (BCX7353): Structure-Guided Design of a Potent, Selective, and Oral Plasma Kallikrein Inhibitor to Prevent Attacks of Hereditary Angioedema (HAE).
    Kotian PL; Wu M; Vadlakonda S; Chintareddy V; Lu P; Juarez L; Kellogg-Yelder D; Chen X; Muppa S; Chambers-Wilson R; Davis Parker C; Williams J; Polach KJ; Zhang W; Raman K; Babu YS
    J Med Chem; 2021 Sep; 64(17):12453-12468. PubMed ID: 34436898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trial.
    Ohsawa I; Honda D; Suzuki Y; Fukuda T; Kohga K; Morita E; Moriwaki S; Ishikawa O; Sasaki Y; Tago M; Chittick G; Cornpropst M; Murray SC; Dobo SM; Nagy E; Van Dyke S; Reese L; Best JM; Iocca H; Collis P; Sheridan WP; Hide M
    Allergy; 2021 Jun; 76(6):1789-1799. PubMed ID: 33247955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orladeyo (Berotralstat): A Novel Oral Therapy for the Prevention of Hereditary Angioedema.
    Powell J; Piszczatoski C; Rubido E
    Ann Pharmacother; 2022 Apr; 56(4):488-493. PubMed ID: 34282650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of oral kallikrein inhibitor berotralstat for hereditary angioedema.
    Gao Y; Hwang J; Hwang G; Craig T
    Drugs Today (Barc); 2022 Feb; 58(2):59-67. PubMed ID: 35188140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of berotralstat for the treatment of hereditary angioedema.
    Farkas H; Balla Z
    Expert Rev Clin Immunol; 2023 Feb; 19(2):145-153. PubMed ID: 36408587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of Recurrent Attacks of Hereditary Angioedema (HAE): Berotralstat and Its Oral Bioavailability.
    Diaz-Menindez M; Morgenstern-Kaplan D; Cuervo-Pardo L; Alvarez-Arango S; Gonzalez-Estrada A
    Ther Clin Risk Manag; 2023; 19():313-317. PubMed ID: 37021074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-Daily Oral Berotralstat for Long-Term Prophylaxis of Hereditary Angioedema: The Open-Label Extension of the APeX-2 Randomized Trial.
    Kiani-Alikhan S; Gower R; Craig T; Wedner HJ; Kinaciyan T; Aygören-Pürsün E; Banerji A; Bernstein JA; Anderson J; Collis P; Johnston DT; Desai B; Tomita D; Gagnon R; Tachdjian R; Soteres DF; Farkas H; Caballero T; McNeil D; Jacobs J; Lumry WR;
    J Allergy Clin Immunol Pract; 2024 Mar; 12(3):733-743.e10. PubMed ID: 38122865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Berotralstat in hereditary angioedema due to C1 inhibitor deficiency: first real-world evidence from a Canadian center.
    Srinivasan C; Ritchie B; Adatia A
    Front Immunol; 2024; 15():1339421. PubMed ID: 38318176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized Trial of the Efficacy and Safety of Berotralstat (BCX7353) as an Oral Prophylactic Therapy for Hereditary Angioedema: Results of APeX-2 Through 48 Weeks (Part 2).
    Wedner HJ; Aygören-Pürsün E; Bernstein J; Craig T; Gower R; Jacobs JS; Johnston DT; Lumry WR; Zuraw BL; Best JM; Iocca HA; Murray SC; Desai B; Nagy E; Sheridan WP; Kiani-Alikhan S
    J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2305-2314.e4. PubMed ID: 33866032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety and effectiveness of berotralstat for hereditary angioedema: The open-label APeX-S study.
    Farkas H; Stobiecki M; Peter J; Kinaciyan T; Maurer M; Aygören-Pürsün E; Kiani-Alikhan S; Wu A; Reshef A; Bygum A; Fain O; Hagin D; Huissoon A; Jeseňák M; Lindsay K; Panovska VG; Steiner UC; Zubrinich C; Best JM; Cornpropst M; Dix D; Dobo SM; Iocca HA; Desai B; Murray SC; Nagy E; Sheridan WP
    Clin Transl Allergy; 2021 Jun; 11(4):e12035. PubMed ID: 34161665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological suppression of the kallikrein kinin system with KVD900: An orally available plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema.
    Duckworth EJ; Murugesan N; Li L; Rushbrooke LJ; Lee DK; De Donatis GM; Maetzel A; Yea CM; Hampton SL; Feener EP
    Clin Exp Allergy; 2022 Sep; 52(9):1059-1070. PubMed ID: 35278245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An expert panel's review on patients with hereditary angioedema switching from attenuated androgens to oral prophylactic therapy.
    Lumry WR; Bernstein JA; Li HH; Levy DS; Jones DH; Padilla BE; Li-Mcleod J; Tachdjian R
    Allergy Asthma Proc; 2024 Jan; 45(1):44-49. PubMed ID: 38151740
    [No Abstract]   [Full Text] [Related]  

  • 19. Oral plasma kallikrein inhibitor BCX7353 for treatment of hereditary angioedema.
    Hwang JR; Hwang G; Johri A; Craig T
    Immunotherapy; 2019 Dec; 11(17):1439-1444. PubMed ID: 31635497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema.
    Aygören-Pürsün E; Bygum A; Grivcheva-Panovska V; Magerl M; Graff J; Steiner UC; Fain O; Huissoon A; Kinaciyan T; Farkas H; Lleonart R; Longhurst HJ; Rae W; Triggiani M; Aberer W; Cancian M; Zanichelli A; Smith WB; Baeza ML; Du-Thanh A; Gompels M; Gonzalez-Quevedo T; Greve J; Guilarte M; Katelaris C; Dobo S; Cornpropst M; Clemons D; Fang L; Collis P; Sheridan W; Maurer M; Cicardi M
    N Engl J Med; 2018 Jul; 379(4):352-362. PubMed ID: 30044938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.